The U.S. healthcare system is grappling with a significant crisis—not due to a shortage of talent or innovation, but rather from issues related to the management, safety, and availability of essential medications. Our reliance on imported drugs is causing alarming shortages and disrupting supply chains, which in turn raises concerns about medication safety.
The crux of the matter is sobering: we have lost control over the medications that we rely on daily.
Back in 2002, the U.S. was producing 83.7% of its drugs. By 2024, that figure plummeted to just 37.1%. During this time, the country’s drug trade deficit has ballooned, hitting a staggering $118.3 billion in 2024. We haven’t merely outsourced manufacturing; we’ve outsourced the protection and reliability of our healthcare system.
This dependence means that nearly two-thirds of the American drug supply is now imported, with many vital medications coming from countries like China and India.
China holds a grip on 80-90% of the global supply of active pharmaceutical ingredients, which are essential for modern medicine. Interestingly, many drugs labeled “Made in the USA” actually have their chemical components produced in China. India, on the other hand, supplies about half of the generic drugs sold in the U.S., with a substantial portion—around 80%—of their active ingredients coming from China as well.
This situation is precarious; it’s not just a supply chain issue—it’s more like a ticking time bomb.
When issues arise, it’s American patients who bear the brunt. In 2023, the FDA had to shut down a single Indian factory that accounted for half of the U.S. supply of a critical cancer drug, cisplatin, after a series of alarming safety violations were uncovered. Without any domestic backup, patients across the nation faced treatment delays.
This wasn’t an isolated incident. There’s only one approved supplier for 40% of our generic drugs, making the whole system vulnerable. If that one facility fails, the consequences could be dire.
Currently, our healthcare system is experiencing extensive drug shortages. Hospital pharmacists report that at any given time, about 301 serious shortages exist, affecting 85% of care scenarios. Doctors are often left without crucial medications, including antibiotics and cancer drugs. These are not obscure medications; rather, they’re fundamental to patient care. Yet, the U.S. doesn’t produce them anymore.
And even when these imported medicines do arrive, safety isn’t guaranteed. A survey conducted in 2025 found that generics from India were 54% more likely to cause serious side effects than their U.S.-made counterparts. There have even been at least eight reported deaths in the U.S. linked to factory violations in India. Concerns about Chinese products are equally serious; back in 2008, contaminated heparin from Chinese suppliers led to numerous American fatalities.
This is not what the American public wants. In a recent survey, about 85% of hospital pharmacists said they’d be willing to pay more for safer generics. But in the current environment, prices often compromise quality, with minimal oversight on drug quality and foreign manufacturers frequently cutting corners.
The federal government also appears out of touch. A 2023 review by the Department of Defense revealed that 22% of essential military medications were obtained without full knowledge about their ingredient sourcing. This presents a significant national security concern.
In April, the Trump administration began investigating the import of common medications, recognizing it as a national security threat. Yet, simply acknowledging the issue is insufficient.
To tackle this crisis, Washington should impose targeted tariffs on common drugs sourced from adversarial countries and work on reshaping domestic drug production through tax incentives and long-term contracts.
Moreover, there’s a pressing need for transparency in drug labeling that reveals where medications and their ingredients are sourced. The FDA must enhance its enforcement, especially overseas, and impose bans on imports from repeat safety offenders. To guarantee key ingredients during market disruptions, a long-term strategy including “strategic drug sanctuaries” is essential.
This goes beyond mere protectionism; it’s about reclaiming American medical independence. If the U.S. can’t produce its own medications, it loses a key aspect of sovereignty. Patients are at risk when healthcare relies on quality assurance from factories thousands of miles away.
For years, we’ve been told that offshoring production leads to lower costs and increased efficiency. However, the U.S. can no longer depend on unreliable foreign suppliers. Now is the time to restore drug independence and take back control of our medicine cabinet.
